ArticleFrontiers in neuroscience2026
Early diagnosis and developmental outcome prediction of agenesis of the corpus callosum via an interpretable deep multimodal fusion model.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Agenesis of the corpus callosum (ACC) presents with highly heterogeneous clinical features. Common methods rarely achieve accurate prenatal or early postnatal diagnosis and prognosis. We aimed to develop and test an interpretable deep neural network (DNN) that combines multimodal clinical data to improve diagnostic accuracy and neurodevelopmental outcome prediction. Methods: We collected data from 205 pediatric patients with ACC at Wuhan Children's Hospital between 2016 and 2024. A total of 27 clinical features were extracted, including neuroimaging findings, perinatal risk factors, and follow-up developmental quotients (Gesell Developmental Schedules and Gross Motor Function scores). Five-fold cross-validation was adopted. We built an eight-layer fully connected DNN with ReLU activation in the hidden layers. For categorical endpoints, a sigmoid output layer with binary cross-entropy loss was used. For continuous endpoints, a linear output layer with mean squared error loss was used. SHAP (Shapley Additive Explanations) values were used to quantify the contribution of individual features to model predictions. Performance was compared with a support vector machine (SVM) baseline and across hyperparameter settings. Area under the receiver-operating-characteristic curve (AUC), F1 score, precision, recall, mean absolute error (MAE), mean squared error (MSE), and coefficient of determination (R Results: Across 12 neurodevelopmental disorders, the model reached an average AUC of 0.97. AUCs for intellectual disability, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), specific learning disorder and developmental coordination disorder ranged from 0.98 to 1.00. Prediction remained moderate for cerebral palsy (AUC = 0.74) and epilepsy (AUC = 0.67). MAE for both Gesell and Gross Motor Function scores was 0.10, with corresponding R Conclusion: The proposed interpretable DNN framework outperforms traditional classifiers in early ACC diagnosis and developmental outcome prediction. It provides a potential tool for clinical decision support. Larger samples and integration of raw imaging data are needed to enhance prediction of complex phenotypes such as cerebral palsy and epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.